Xenon Pharmaceuticals Inc. (XENE)
| Market Cap | 6.12B +138.7% |
| Revenue (ttm) | n/a |
| Net Income | -409.20M |
| EPS | -4.73 |
| Shares Out | 96.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 665,620 |
| Open | 64.50 |
| Previous Close | 64.23 |
| Day's Range | 62.82 - 64.95 |
| 52-Week Range | 32.78 - 72.66 |
| Beta | 0.63 |
| Analysts | Strong Buy |
| Price Target | 81.30 (+28.6%) |
| Earnings Date | Aug 6, 2026 |
About XENE
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price target is $81.3, which is an increase of 28.60% from the latest price.
News
Xenon Pharmaceuticals price target lowered to $81 from $82 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $81 from $82 and keeps an Outperform rating on the shares.
Xenon Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 revenue grew 3% year-over-year (excluding non-recurring items), driven by strong consumables growth and exceptional demand for the new Atera platform. Instrument revenue declined as customers awaited Atera, but full-year guidance was raised on robust order flow and margin expansion.
Xenon Pharmaceuticals Earnings release: Q2 2026
Xenon Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Xenon Pharmaceuticals Quarterly report: Q2 2026
Xenon Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Xenon Pharmaceuticals reports Q2 EPS ($1.11), consensus ($1.16)
“The second quarter of 2026 was marked by strong execution, including a successful pre-NDA meeting, and the NDA submission for azetukalner remains on track for the third quarter of 2026.
Xenon Reports Q2 2026 Financial Results and Provides Business Update
NDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue to enroll Three Phase 3 studies of azetukalner i...
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical develo...
Xenon to Report Q2 2026 Financial Results on August 6, 2026
VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical develo...
Xenon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Azetukalner demonstrated best-in-class efficacy in phase III epilepsy trials, with NDA filing planned for Q3 and commercial launch expected in late 2027. The pipeline includes advanced psychiatry and pain programs, with key MDD data in H1 2027 and strong financials supporting broad market expansion.
Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan
JPMorgan raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $82 from $80 and keeps a Neutral rating on the shares. The firm updated the company’s model. Published first…
Xenon Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
Azetukalner demonstrated best-in-class efficacy in refractory focal onset epilepsy, with strong long-term seizure freedom rates and a favorable safety profile. NDA submission is planned for Q3, with a robust commercial launch strategy targeting both specialists and general neurologists. Pipeline includes phase III MDD and phase I pain programs.
Xenon Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Azetukalner showed strong efficacy and safety in epilepsy trials, with NDA submission planned for Q3 and a standard 12-month review. Its novel mechanism, good tolerability, and flexible dosing support broad use. Commercial efforts target specialists and general neurologists. Premium pricing, international partnerships, and phase III MDD data are expected next year.
Xenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan
JPMorgan analyst Tessa Romero raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $80 from $77 and keeps an Overweight rating on the shares.
Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo
Wells Fargo analyst Benjamin Burnett raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $69 from $68 and keeps an Overweight rating on the shares. The firm sees a…
Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
Needham analyst Serge Belanger lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $78 from $80 and keeps a Buy rating on the shares.
Xenon Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw strong clinical and financial progress, with AZK's phase III data exceeding expectations and a $747.5M financing extending cash runway into 2029. NDA submission for AZK is planned for Q3 2026, with commercial and pipeline readiness advancing.
Xenon Pharmaceuticals Earnings release: Q1 2026
Xenon Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Xenon Pharmaceuticals Quarterly report: Q1 2026
Xenon Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Xenon Reports Q1 2026 Financial Results and Provides Business Update
VANCOUVER, British Columbia and BOSTON, MA, May 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, cl...
Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026
Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trials, treatment response, and pediatric lung disease.
Xenon to Report Q1 2026 Financial Results on May 7, 2026
VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
Xenon Pharmaceuticals Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
Azetukalner demonstrated best-in-class efficacy and rapid onset in phase III epilepsy trials, with long-term data showing sustained seizure reduction and strong safety. Expansion into psychiatry and pain indications is underway, supported by robust financials and a growing pipeline.
Xenon Pharmaceuticals Proxy statement: Proxy filing
Xenon Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Xenon Pharmaceuticals Proxy statement: Proxy filing
Xenon Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
Xenon Pharmaceuticals (XENE) presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures at the American Academy of Neurology Ann...